Outcome by stroke etiology in patients receiving thrombolytic treatment descriptive subtype analysis

Stroke

Volumn 42, Issue 1, 2011, Pages 102-106

  Mustanoja, Satu ^a   Meretoja, Atte ^a   Putaala, Jukka ^a   Viitanen, Varpu ^a   Curtze, Sami ^a   Atula, Sari ^a   Artto, Ville ^a   Häppölä, Olli ^a   Kaste, Markku ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Clinical outcome; Ischemic stroke; Small vessel disease; Stroke subclassification; Thrombolysis; TOAST criteria

Indexed keywords

GLUCOSE; HEPARIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOEMBOLISM; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LARGE ARTERY ATHEROSCLEROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RANKIN SCALE; SEX RATIO; SMALL VESSEL VASCULITIS; STROKE; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; DIABETES COMPLICATIONS; EMBOLISM; FEMALE; FINLAND; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRACRANIAL HEMORRHAGES; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY;

EID: 79451473691     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.597534     Document Type: Article

References (17)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Cocho D, Belvís R, Martí-Fábregas J, Bravo Y, Aleu A, Pagonabarraga J, Molina-Porcel L, Díaz-Manera J, San Roman L, Martínez-Lage M, Martínez A, Moreno M, Martí-Vilalta JL. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol. 2006;55:70-73.
4. Hwang YH, Seo JG, Lee HW, Park SP, Suh CK. Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke. Cerebrovasc Dis. 2008;26:355-359.
5. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, Häppölä O, Lindsberg P, Mustanoja S, Piironen K, Pitkäniemi J, Rantanen K, Sairanen T, Salonen O, Silvennoinen H, Soinne L, Strbian D, Tiainen M, Kaste M. Off-label thrombolysis is not associated with poor outcome in stroke patients. Stroke. 2010;41:1450-1458.
6. Lindsberg PJ, Soinne L, Tatlisumak T, Roine RO, Kallela M, Happola O, Kaste M. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA. 2004;292:1862-1866.
7. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III; the TOAST investigators. Classification of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
8. Fluri F, Hatz F, Rutgers MP, Georgiadis D, Sekoranja L, Schwegler G, Sarikaya H, Weder B, Müller F, Lüthy R, Arnold M, Reichhart M, Mattle HP, Tettenborn B, Nedeltchev K, Hungerbühler HJ, Sztajzel R, Baumgartner RW, Michel P, Lyrer PA, Engelter ST. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol. 2010;17:1054-1060.
9. Hsia AW, Sachdev HS, Tomlinson RN, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke. Does stroke subtype really matter? Neurology. 2003;61:71-75.
10. Demchuk AM, Khan F, Hill MD, Barber PA, Silver B, Patel S, Levine SR. NINDS rt-PA Stroke Study Group. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008;26:120-125.
11. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004; 62:569-573.
12. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Practical Neurology. 2008;8:222-228.
13. Toni D, Iweins F, von Kummer R, Busse O, Bogousslavsky J, Falcou A, Lesaffre E, Lenzi GL; for the ECASS I Group. Identification of lacunar infarcts before thrombolysis in the ECASS I study. Neurology: 2000;54:679-684.
14. Lammie GA. Pathology of small vessel stroke. Br Med Bull. 2000;56: 296-306.
15. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke. 2000;31:1081-1089.
16. Lees K, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
17. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, Schwamm LH, GWTG-Stroke Steering Committee and Investigators. The 'golden hour' and acute brain ischemia: presenting features and lytic therapy in >30 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-1439.